Court Opinion in Sanofi-Aventis U.S., LLC, and Novo Nordisk Challenges to 340B Contract Pharmacies Obligations

November 5, 2021
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

SANOFI-AVENTIS U.S., LLC,

                                   Plaintiff,
v.                                                                        Civil Action No. 21-00634 (FLW)

U.S. DEPARTMENT OF HEALTH AND                                 OPINION
HUMAN SERVICES, et. al.,

                                  Defendants.

______________________________

NOVO NORDISK INC.,

                                  Plaintiff,
v.                                                                    Civil Action No. 21-00806 (FLW)

U.S. DEPARTMENT OF HEALTH AND
HUMAN SERVICES, et. al.,

                                   Defendants.

WOLFSON, Chief Judge:

Plaintiffs Sanofi-Aventis U.S., LLC, and Novo Nordisk Inc.1 sue the United States
Department of Health and Human Services (“HHS”), former HHS Secretary Alex M. Azar II, former HHS General Counsel Robert P. Charrow, Acting HHS Secretary Norris Cochran, Acting HHS General Counsel Daniel J. Berry, the Health Resources and Services Administration (“HRSA”), former HRSA Administrator Thomas J. Engels, and Acting HRSA Administrator Diana Esposito (collectively, “the Government”) for agency action relating to “the 340B Program,” a drug-purchasing provision in the Veterans Health Care Act, Pub. L. No. 102-585, 106 Stat. 4943, 4967-71 (1992), codified at the Public Health Services Act, Pub. L. No. 78-410, 58 Stat. 682 (1992); 42 U.S.C. § 256b.

View the entire Court Opinion below.